Common marmoset embryonic stem cell lines

• US 20060177926A1
• Filed: 09/02/2005
• Published: 08/10/2006
• Est. Priority Date: 09/07/2004
• Status: Abandoned Application

• Current Assignee: Center For The Advancement of Health and Bioscience, The Central Institute for Experimental Animals
• Original Assignee: Center For The Advancement of Health and Bioscience, The Central Institute for Experimental Animals
• Inventors: Sasaki, Erika, Tani, Kenzaburo, Okano, Hideyuki, Tanioka, Yoshikuni
• Application Number:
  US11/218,699
• Publication Number:
  US 20060177926A1
• Time in Patent Office: Days
• US Class Current: 435/363
• CPC Class Codes: C12N 2502/13 connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
• CPC Class Codes: C12N 5/0606 Pluripotent embryonic cells, e.g. embryonic stem cells [ES] embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696

Abstract

The present invention relates to novel common marmoset (Callithrix jacchus) embryonic stem cell cultures and cell lines, and their use. The common marmoset embryonic cells of the present invention (i) are capable of prolonged undifferentiated proliferation in vitro, (ii) maintain, during prolonged culture, a karyotype in which all the chromosomal characteristics of common marmoset are present without noticeable alteration; (iii) are capable of differentiation into all three embryonic germ layers (ectoderm, endoderm and mesoderm) even after prolonged culture; and (iv) are capable of teratoma formation in vivo. The stem cells preferably are totipotent.

Claims

1. A purified preparation of embryonic stem cells derived from common marmoset (Callithrix jacchus), which (i) is capable of prolonged undifferentiated proliferation in vitro, (ii) maintains, during prolonged culture, a karyotype in which all the chromosomal characteristics of common marmoset are present without noticeable alteration;

(iii) is capable of differentiation into all three embryonic germ layers (ectoderm, endoderm and mesoderm) even after prolonged culture; and

(iv) is capable of teratoma formation in vivo.

2. The purified preparation of claim 1 wherein said embryonic stem cells are totipotent.

3. The purified preparation of claim 1 wherein the stem cells are positive for the SSEA-3, SSEA-4, TRA1-60, and TRA1-81 markers, and negative for the SSEA-1 marker.

4. The purified preparation of claim 3 wherein the stem cells additionally express one or more of the cell markers selected from the group consisting of Nanog, Oct3/4, Sox2, gp130, mCG, HEB and Bex1/Rex3.

5. The purified preparation of claim 4 wherein the stem cells exhibit high telomerase activity.

6. The purified preparation of claim 1 wherein the stem cells are capable of undifferentiated proliferation in vitro for at least 3 months.

7. The purified preparation of claim 1 wherein the stem cells are capable of undifferentiated proliferation in vitro for at least 6 months.

8. The purified preparation of claim 1 wherein the stem cells are capable of undifferentiated proliferation in vitro for at least one year.

9. The purified preparation of claim 1 capable of differentiation into all three embryonic germ layers after continuous culture for at least 3 months.

10. The purified preparation of claim 1 capable of differentiation into all three embryonic germ layers after continuous culture for at least 6 months.

11. The purified preparation of claim 1 capable of differentiation into all three embryonic germ layers after continuous culture for at least one year.

15. A method of making a genetically modified common marmoset (Callithrix jacchus), comprising

(a) introducing a mutation into a stem cell according to claim 1, and

(b) transplanting said stem cell into said common marmoset.

16. The method of claim 15 further comprising the step of analyzing the differentiation and proliferation of said stem cells in said common marmoset.

17. The assay method of claim 16 wherein said stem cells have a foreign gene introduced thereinto.

12. A cell line developed from embryonic stem cells of common marmoset (Callithrix jacchus), which (i) is capable of prolonged undifferentiated proliferation in vitro, (ii) maintains, during prolonged culture, a karyotype in which all the chromosomal characteristics of common marmoset are present without noticeable alteration;

and (iii) is capable of differentiation into all three embryonic germ layers (ectoderm, endoderm and mesoderm) even after prolonged culture, and (iv) is capable of teratoma formation in vivo.

13. The cell line of claim 12 which is positive for the SSEA-3, SSEA-4, TRA1-60, and TRA1-81 markers, and negative for the SSEA-1 marker.

14. The cell line of claim 13 which additionally expresses one or more of the cell markers selected from the group consisting of Nanog, Oct3/4, Sox2, gp130, mCG, HEB and Bex1/Rex3.

18. A common marmoset (Callithrix jacchus) carrying a genetic modification resulting from the introduction into said common marmoset genetically modified common marmoset embryonic stem cells which (i) are capable of prolonged undifferentiated proliferation in vitro, (ii) maintain, during prolonged culture, a karyotype in which all the chromosomal characteristics of common marmoset are present without noticeable alteration;

(iii) are capable of differentiation into all three embryonic germ layers (ectoderm, endoderm and mesoderm) even after prolonged culture; and

(iv) are capable of teratoma formation in vivo.

19. The common marmoset of claim 18 wherein said stem cells are totipotent.

20. An immunodeficient rodent having embryonic stem cells of common marmoset (Callithrix jacchus) transplanted therein, wherein said cells (i) are capable of prolonged undifferentiated proliferation in vitro, (ii) maintain, during prolonged culture, a karyotype in which all the chromosomal characteristics of common marmoset are present without noticeable alteration;

(iii) are capable of differentiation into all three embryonic germ layers (ectoderm, endoderm and mesoderm) even after prolonged culture, and (iv) are capable of teratoma formation in vivo.

21. The immunodeficient rodent of claim 20 wherein said stem cells are totipotent.

22. The method of claim 20 wherein said rodent is a mouse or a rat.

23. The method of claim 22 wherein said mouse is selected from the group consisting of athymic nude mouse, C.B-17/severe combined immunodeficiency (scid) mouse and NOD/SCID mouse.

24. The method of claim 23 wherein said mouse is a NOD/SCID/γ

_c^null mouse.

25. The mouse of claim 23 wherein said mouse additionally carries a transgene.

26. The mouse of claim 25 wherein said mouse is an animal model of a disease or condition susceptible to cell based therapy.

27. The method of claim 26 wherein said disease or condition is selected from the group consisting of Parkinson'"'"'s disease, diabetes, traumatic spinal cord injury, Purkinje cell degeneration, Duchenne'"'"'s muscular dystrophy, heart disease, vision loss and hearing loss.

28. The method of claim 20 wherein said embryonic stem cells are in the form of embryoid bodies.

29. The method of claim 20 wherein said embryonic stem cells are in a differentiated form.

30. The method of claim 29 wherein the differentiated stem cells are selected from the group consisting of muscle cells, nerve cells, and blood cells.